Lonza Expands Cell Culture Med Portfolio

Lonza has expanded its cell culture media portfolio with the addition of the GSv9™ Media and Feeds, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System®. The new chemically defined, animal-component free media and feeds are easy to implement, highly robust and enable greater batch-to-batch consistency. As a result, biopharmaceutical manufacturers can more easily develop streamlined and scalable bioproduction processes.

Recombinant proteins derived from mammalian cell lines are a key source of biopharmaceuticals designed to treat many complex human diseases. However, in such a highly competitive market, biopharmaceutical manufacturers must ensure that they maximize protein yield and consistency whilst also expediting production times. One way to achieve this is by using specially developed, simple-to-use media and feeds that improve cellular productivity, streamline processing and eliminate sources of product variability.

“Developing a commercially successful bioproduction process hinges on having a robust culturing platform that can reproducibly generate high-quality, stable proteins. The GSv9™ Media and Feeds have been designed with these challenges in mind, offering an easy-to-use solution for customers using our GS Gene Expression System®. Drawing on more than 35 years of mammalian expression, process development and manufacturing experience, GSv9™ Media and Feeds is a newly developed highly robust platform that maximizes cell concentration and protein yields while cutting production time. As a result, we’re helping our customers to accelerate time to market for the next generation of therapeutics,” Colin Jaques, Technical Director, Lonza Biologics said.